# Resveratrol Skin Aging Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/resveratrol-skin-aging-randomized-trial-evidence-review
Category: evidence-review
Summary: Resveratrol Skin Aging Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are
Last reviewed: 2026-07-06
Reviewed by: Migaku Evidence Review
# Resveratrol Skin Aging Randomized Trial: What the Evidence Says

## Quick Answer

Resveratrol Skin Aging Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 randomized trial, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Liposomal Delivery Enhances the Effects of a Collagen Tripeptide–Containing Formulation on Dermal Structure and Optical Skin Parameters: A Randomized, Double‐Blind, Placebo‐Controlled Trial | randomized trial | 2 | 2026-03-31 | 10.1111/jocd.70834 |
| Piceatannol from Passion Fruit Seed Waste: A Circular Bioeconomy-Driven Pathway Toward a Skin-Targeted Bioactive | narrative review | 3 | 2026-04-12 | 10.3390/ijms27083451 |

## What The Sources Report

- These factors collectively disrupt dermal extracellular matrix (ECM) homeostasis, leading to reduced collagen synthesis, impaired elasticity, decreased hydration, and the progressive development of wrinkles and uneven skin appearance. [Lin Yung‐Kai (2026); evidence level 2]
- Although liposomal formulations have been extensively explored in experimental and topical contexts, clinical evidence directly comparing liposomal and nonliposomal oral formulations containing collagen tripeptides with respect to skin functional outcomes remains limited. [Lin Yung‐Kai (2026); evidence level 2]
- Notably, the concentration of PIC required for certain in vitro activities remains higher than those typically achieved in vivo, and the current evidence base for PIC in human skin is considerably less developed than that for resveratrol. [Zhang Dian (2026); evidence level 3]
- We aim to: (1) synthesize the evidence for PIC's multi-target activity in skin aging and acne; (2) critically evaluate existing in vivo and clinical data to identify key evidence gaps; and (3) propose a phase-gate translational framework that prioritizes standardization, sustainable sourcing, nano-delivery, and clinical validation. [Zhang Dian (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For resveratrol skin aging randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Lin Yung‐Kai (2026). Liposomal Delivery Enhances the Effects of a Collagen Tripeptide–Containing Formulation on Dermal Structure and Optical Skin Parameters: A Randomized, Double‐Blind, Placebo‐Controlled Trial. DOI: 10.1111/jocd.70834. PMCID: PMC13039767. PMID: 41918155. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13039767/
- Zhang Dian (2026). Piceatannol from Passion Fruit Seed Waste: A Circular Bioeconomy-Driven Pathway Toward a Skin-Targeted Bioactive. DOI: 10.3390/ijms27083451. PMCID: PMC13116525. PMID: 42074094. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13116525/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.